 Treatment: Trastuzumab emtansine T-DM1 will be administered at a fixed dose of 3.6 mgkg IV on Day 1 every 3 weeks and three cohorts of patients with three different dose levels of conventional non-pegylated liposomal doxorubicin 45 mgm2, 50 mgm2 and 60 mgm2 IV on Day 1 in cycles of 21 days each are planned. 